ACSL1 (acyl-CoA synthetase 1), the major acyl-CoA synthetase of adipocytes, has been proposed to function in adipocytes as mediating free fatty acid influx, esterification, and storage as triglyceride. To test this hypothesis, ACSL1 was stably silenced (knockdown (kd)) in 3T3-L1 cells, differentiated into adipocytes, and evaluated for changes in lipid metabolism. Surprisingly, ACSL1-silenced adipocytes exhibited no significant changes in basal or insulin-stimulated long-chain fatty acid uptake, lipid droplet size, or tri-, di-, or monoacylglycerol levels when compared with a control adipocyte line. However, ACSL1 kd adipocytes displayed a 7-fold increase in basal and a ϳ15% increase in forskolin-stimulated fatty acid efflux without any change in glycerol release, indicating a role for the protein in fatty acid reesterification following lipolysis. Consistent with this proposition, ACSL1 kd cells exhibited a decrease in activation and phosphorylation of AMP-activated protein kinase and its primary substrate acetyl-CoA carboxylase. Moreover, ACSL1 kd adipocytes displayed an increase in phosphorylated protein kinase C and phosphorylated JNK, attenuated insulin signaling, and a decrease in insulin-stimulated glucose uptake. These findings identify a primary role of ACSL1 in adipocytes not in control of lipid influx, as previously considered, but in lipid efflux and fatty acid-induced insulin resistance.
Fatty acid influx and efflux mechanisms and their regulation affect lipid storage and metabolism in adipocytes. Imbalances in adipose lipid metabolism have been shown to significantly contribute to the development of obesity and associated metabolic diseases, such as type 2 diabetes, hypertension, and cardiovascular disease (1) (2) (3) . Although the molecular mechanisms involved in fatty acid efflux are still undefined, several proteins implicated in fatty acid influx have been proposed: CD36 (fatty acid translocase), acyl-CoA synthetases (fatty acid transport protein (FATP) 2 and acyl-CoA synthetase (ACSL) family members), plasma membrane fatty acid-binding protein, and caveolin-1 (4 -9).
FATPs and long-chain ACSLs are membrane-bound enzymes that catalyze the ATP-dependent esterification of long chain (ACSL) and very long-chain (FATP) fatty acids to their acyl-CoA derivatives (10, 11) . Both types of CoA synthetases have common ATP/AMP binding and fatty acid binding signature motifs. In mammals, six different isoforms of FATP (FATP1-FATP6) and five different isoforms of ACSL (ACSL1, -3, -4, -5, and -6) have been identified with tissue-specific expression patterns (12) . White adipose tissue predominantly express FATP1, FATP4, and ACSL1, whereas brown adipose tissue in addition expresses ACSL5. Our recent results have confirmed a major role of FATP1 and CD36, but not FATP4, in insulin-stimulated LCFA uptake in 3T3-L1 adipocytes (6) .
ACSL1 is a ϳ78-kDa intrinsic membrane protein localized to multiple sites in a variety of different cells. In liver, ACSL1 has been shown to be localized to the endoplasmic reticulum and mitochondria-associated membranes, whereas in adipocytes, ACSL1 was also found associated with the plasma membrane, the lipid droplet surface (13) , and glucose transporter 4-containing vesicles (14, 15) . Recent studies have postulated a cooperative role of FATP1 and ACSL1 in the movement of LCFAs across the plasma membrane via a process termed vectoral acylation (16) , in which the CoA-and ATP-dependent esterification of internalized fatty acid provides the thermodynamic force necessary for net lipid influx. Evidence supporting this hypothesis came from a functional cloning strategy that identified mouse ACSL1 along with FATP1 as proteins involved in LCFA transport (17) . In contrast to the role of ACSL1 in LCFA uptake and triglyceride synthesis in adipocytes, overexpression of ACSL1 in rat primary hepatocytes channeled fatty acids toward diacylglycerol and phospholipids synthesis and increased reacylation of hydrolyzed fatty acids into triglyceride (18) .
Since lipid flux is defined by the location and activity of its regulatory enzymes and proteins, overexpression strategies can result in changes in metabolism potentially distinct from the endogenous function. To that end, our laboratory has recently undertaken a gene silencing approach to the evaluation of proteins implicated in adipocyte fatty acid influx and efflux, and prior studies have focused on FATP1, FATP4, and CD36 (6) . In this report, we evaluated the adipose-specific role(s) of ACSL1 using stable gene-silencing strategies in 3T3-L1 adipocytes using lentiviral delivery of shRNA. We report herein that, contrary to previous reports, in 3T3-L1 adipocytes, ACSL1 does not facilitate the basal or insulin-stimulated component of LCFA uptake. ACSL1 is, however, involved in the reesterification of hydrolyzed fatty acids released during basal and forsko-lin-stimulated lipolysis, thereby regulating their availability and efflux from the cell. Additionally, fatty acid reesterification by ACSL1 during lipolysis plays a major role in regulating the AMP-activated protein kinase (AMPK) as well as the PKC and JNK pathways leading to insulin resistance. Such findings bring to light a new interpretation of the role of ACSL1 and other acyl-CoA synthetases in the control of intermediary metabolism and lipid-mediated signal transduction. ) were obtained from Cell Signaling Technology. Rabbit anti-FATP4 was a gift of Dr. Paul Watkins (Baltimore, MD). An anti-ACSL1 polyclonal antibody was generated against a synthetic peptide (DLGRVNRVKPKPPEPEDL) by BioWorld (Dublin, OH), precipitated with 40% saturated ammonium sulfate, and resolubilized at 1 mg/ml in phosphate buffered saline for use. For detection, horseradish peroxidase-coupled IgGs were obtained from Jackson ImmunoResearch Laboratories, Inc.
EXPERIMENTAL PROCEDURES

Materials
Cell Culture Conditions-3T3-L1 preadipocytes were cultured and differentiated into adipocytes, as described previously (19) . Briefly, preadipocytes were cultured in Dulbecco's modified Eagle's medium with 10% calf serum. Two days after reaching confluence, the cells were induced to differentiate in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 174 nM insulin, 0.5 mM methylisobutylxanthine, and 0.25 M dexamethasone. Two days following the initiation of cellular differentiation, dexamethasone and methylisobutylxanthine were withdrawn from the medium. Insulin was withdrawn from the medium 4 days after initiation of differentiation. Differentiated adipocytes were maintained in Dulbecco's modified Eagle's medium and 10% fetal bovine serum until mature (days 8 -12) .
Generation of ACSL1 kd and CD36 kd in 3T3-L1 Adipocytes Using Lentivirus-delivered RNA Interference-A lentivirusbased RNA interference vector pLKO1 (kindly provided by Sheila Stewart (Whitehead institute, Cambridge, MA) was used for generation of recombinant lentivirus expressing shRNA targeting ACSL1 and CD36 using methods previously described (20) . Briefly, oligomers 60 bp in length containing a stem-loop structure directed against either ACSL1 or CD36 were synthesized and cloned into the AgeI/EcoRI site in pLKO1. Four small interfering RNA sequence variants of each gene were synthesized. Recombinant lentiviruses expressing each of the sequence variants for both genes were packaged in 293T cells and harvested 48 h later. 3T3-L1 fibroblasts were transduced with the lentiviruses for 4 -6 h in the presence of 6 g/ml polybrene at a multiplicity of infection of ϳ50 -100. Cells were allowed to recover for 48 h post-transduction before the addition of selection medium containing 3 g/ml puromycin. Multiple stable knockdown cell lines were generated from a heterogeneous pool of puromycin-resistant 3T3-L1 fibroblasts.
Relative gene silencing efficiencies of the different knockdown cell lines were analyzed using real time PCR. Real time PCR primers used for transcriptional analysis of ACSL1 and CD36 were designed earlier, as described (21) . The expression of the indicated targets was normalized to that of ␤-actin: forward primer, 5Ј-CAAAAGCCACCCCCACTCCTAAGA-3Ј; reverse primer, 5Ј-GCCCTGGCTGCCTCAACACCTC-3Ј. Cell lines with the greatest gene knockdown were selected for further analysis. The oligomers targeting the ACSL1 nucleotide sequence were 5Ј-CGACTGCTCAGGTTT-TATA-3Ј (ACSL1-3, nucleotide positions 888 -906) and 5-CCCTATGAGTGGATTTCC-3Ј (ACSL1-2, nucleotide positions 352-369), and that targeting the CD36 nucleotide sequence was 5Ј-GGGAAGTTGTCCTTGAAGA-3Ј (nucleotide positions 119 -137). A construct expressing shRNA against a scrambled sequence (5Ј-AGTACTGCTTACGAT-ACGG-3Ј) was used as a control.
Fatty Acyl-CoA Synthetase Assays-The acyl-CoA synthetase activity of extracts was measured by the conversion of 3 H-labeled fatty acids to their CoA derivatives by a modified method from Nagamatsu et al. (22) , as described previously (10, 11) .
Analysis of Cellular Fatty Acid Uptake and Lipid PoolsFatty acid uptake in 3T3-L1 adipocytes (day 8) was carried out as described earlier (6) with the following modifications. Adipocytes were preincubated for 2 h in Krebs-Ringer Hepes (KRH) buffer (pH 7.4) containing 120 mM NaCl, 4.7 mM KCl, 2.2 mM CaCl 2 , 10 mM HEPES, 1.2 mM KH 2 PO 4 , 1.2 mM MgSO 4 , 0.1% fatty acid-free bovine serum albumin (BSA), and 5.4 mM glucose. Adipocytes were incubated either with or without insulin (50 nM) for 30 min. The assays were carried out in the presence or absence of a general lipase inhibitor, E600 (100 M). Fatty acid uptake was initiated by incubating cells for a minute in KRH buffer, pH 7.4, containing 5.4 mM glucose and 3 H-labeled palmitic, oleic, or arachadonic acid, each bound to 50 M fatty acid-free BSA in a ratio adjusted to generate a free fatty acid concentration of 20 nM. The cells were washed, and cellular incorporated radioactivity was determined.
To analyze lipid pools, 3T3-L1 adipocytes (day 8) were preincubated for 2 h in KRH buffer and stimulated with insulin or 20 M forskolin for 30 min. The cellular lipids were then extracted with chloroform/methanol (2:1). The organic phase was dried, resolubilized in a minimal volume of chloroform, and bound to disposable primary aminopropyl-bonded phase columns. The various polar and neutral classes of lipids were eluted by organic fractionation using the procedures outlined by Kaluzny et al. (23) . Cellular tri-, di-, and monoacylglycerol lipids were quantitated by alkaline hydrolysis and measurement of glycerol content using the glycerol determination kit (Sigma). Fatty acids were measured using the nonesterified fatty acid kit (Wako).
Glucose Uptake, Lipogenesis, and Lipolysis-[ 3 H]2-Deoxy-Dglucose uptake in 3T3-L1 adipocytes was carried out as described previously (6) . To measure de novo lipogenesis in 3T3-L1 adipocytes, the method described by Mackall et al. (24) was employed. Briefly, 3T3-L1 adipocytes serum-starved in KRH for 2 h, were incubated at 37°C for 30 min with 5 mM [1-
14 C]acetate (3 ϫ 10 5 dpm/mol) and 100 M E600 in the presence or absence of 100 nM insulin in KRH without BSA. De novo lipogenesis was also measured in serum-starved 3T3-L1 adipocytes treated with 20 M forskolin in KRH containing 0.5% BSA in the absence of E600. The cells were extracted twice with chloroform/methanol (2:1). The organic layer was dried under nitrogen, and the radioactivity incorporated into the total lipid pool was quantified by liquid scintillation counting. In experiments with forskolin treatments, both cell extracts as well as extracellular media were assayed for labeled de novo synthesized lipids.
For studies of lipolysis, 3T3-L1 adipocytes (day 8) were preincubated for 2 h in KRH buffer (pH 7.4). Hormone-stimulated and basal lipolysis was initiated with and without the addition of 20 M forskolin in KRH containing 0.5% BSA. The extracellular medium was collected after 30 min and analyzed for glycerol and fatty acid release.
Fatty Acid Oxidation-3T3-L1 adipocytes were incubated for 24 h in Dulbecco's modified Eagle's medium and 10% fetal bovine serum plus 1 mM L-carnitine. Adipocytes were subsequently serum-starved for 1 h in KRH containing 5.4 mM glucose, 1 mM L-carnitine, and 0.1% fatty acid-free BSA. ␤-Oxidation was initiated upon the addition of 400 M [1-
14 C]palmitate (2 Ci/ mol palmitate), buffered with 0.7% fatty acid-free BSA, and incubated for 60 min at 37°C and 5% CO 2 . Media and cells were transferred to glass vials containing a center well filled with 400 l of 1 M NaOH. 200 l of 70% perchloric acid was injected into the glass vials, capped with a rubber stopper, and incubated with gentle agitation for 1 h at room temperature. Center wells were transferred to liquid scintillation fluid, and 14 CO 2 was counted. The remaining acidified sample was centrifuged at 13,000 ϫ g at 4°C. Supernatant was added to liquid scintillation fluid, and 14 C-labeled acid-soluble metabolites were counted.
RESULTS
Characterization of ACSL1-silenced 3T3-L1 Adipocytes-
Several stable lines of 3T3-L1 adipocytes expressing lentivirusderived shRNA sequence variants targeting ACSL1 were developed and analyzed for the expression of ACSL1 mRNA. Based on real time PCR analysis, two cell lines, ACSL1-3 kd and ACSL1-2 kd, were selected for further analysis, since they exhibited the greatest decrease in ACSL1 mRNA expression as compared with the adipocytes expressing a scrambled sequence shRNA (Scr) as a control. ACSL1 mRNA expression was reduced ϳ70 -80% and 40 -50% in ACSL1-3 kd and ACSL1-2 kd adipocytes, respectively, when compared with the control (Fig. 1A) . No statistically significant decrease in ACSL1 mRNA abundance was observed between the Scr cell line and untransfected wild type 3T3-L1 adipocytes. Consistent with the decrease in mRNA, immunoblot analysis of ACSL1-3 kd revealed a ϳ60 -70% decrease in ACSL1 protein expression compared with Scr cells (Fig. 1B) . In general, ACSL1-3 kd and ACSL1-2 kd preadipocytes grew at a normal rate and differentiated in a manner indistinguishable from control cells using the standard methylisobutylxanthine, dexamethasone, and insulin regimen. Immunoblotting of protein extracts from ACSL1-3 kd and control cells revealed unchanged expression of key adipogenic transcription factors, such as peroxisome proliferator-activated receptor ␥ and CCAAT/enhancer-binding protein ␣ (Fig. 1B) and their target genes, AFABP/aP2 (adipo- cyte fatty acid-binding protein) and CD36. The ACSL1-silenced adipocytes exhibited a slight increase in the expression of FATP1, whereas the levels of another acyl-CoA synthetase, FATP4, were unaltered.
ACSL1 has been shown in prior studies to utilize a broad range of fatty acid substrates for acyl-CoA formation. Whereas the substrate specificity ranges from C12 to C24, the catalytic efficacy of the enzyme directed toward various chain length fatty acids varies considerably. ACSL1 is ϳ10-fold more active toward C16:0 than C24:0 (11). To evaluate the effect of ACSL1 silencing on total cellular acyl-CoA synthetase activity, adipocyte cell extracts were assayed for fatty acid esterification using a variety of lipid substrates. As shown in Table 1 , silencing of ACSL1 resulted in a 50 -75% decrease in total cellular acyl-CoA synthetase activity over a broad range of lipid substrates. These results establish ACSL1 as the major acyl-CoA synthetase of 3T3-L1 adipocytes.
As shown in Fig. 2 , under basal conditions, the levels of cellular fatty acid, tri-, di-, and monoacylglycerol were unaltered between Scr and ACSL1-3 kd adipocytes. Consistent with this, Oil Red O staining of triacylglycerol droplets exhibited no visual differences between ACSL1-3 kd 3T3-L1 adipocytes relative to the scrambled control (data not shown). However, when incubated with 100 nM insulin for 30 min, the ACSL1-3 kd adipocytes displayed a small but statistically significant increase in the triacylglycerol (TAG)
Lipid Metabolism in ACSL1-silenced 3T3-L1 AdipocytesThe role of ACSL1 in fatty acid efflux was assessed by measuring glycerol and fatty acid release under both basal and forskolin-stimulated conditions in Scr, ACSL1-3 kd, and ACSL1-2 kd adipocytes. As shown in Fig. 3 insulin (Fig. 4A) . Our earlier studies on adipocyte fatty acid influx demonstrated that postuptake, fatty acids are rapidly esterified with CoA and incorporated predominantly into the TAG droplet (6). Since ACSL1-silenced adipocytes exhibit increased fatty acid efflux after triglyceride lipolysis, and also since insulin blocks lipolysis, the apparent decrease in basal palmitate influx could be the result of hydrolysis of newly synthesized TAG and efflux of resulting fatty acids occurring concomitant with influx. To address this possibility, the influx of [ 3 H]palmitate into both cell types was carried out in the presence of E600, a lipase inhibitor, to block triglyceride lipolysis and subsequent fatty acid efflux. Confirming our hypothesis, as shown in Fig. 4A , the decrease in fatty acid influx observed in ACSL1-3 kd adipocytes when compared with Scr was eliminated when assay conditions were modified to include E600. Fatty acid influx experiments with [ 3 H]fatty acids of different chain lengths indicated that silencing of ACSL1 had no effect on the influx of palmitate, oleate, or arachidonate under both basal and insulin-stimulated conditions, as shown in Fig. 4B . Overall, these studies demonstrate that under basal conditions, concomitant fatty acid influx and efflux does occur, but when corrected for by using E600, ACSL1-silenced adipocytes exhibit no change in lipid influx. ACSL1-2 adipocytes, expressing another ACSL1 shRNA sequence variant, also demonstrated unaffected basal and insulin-stimulated palmitate influx when compared with Scr adipocytes (Fig. 4C) . As a control and consistent with the results of Abumrad and co-workers (5), silencing of CD36 resulted in a 35-40% decrease in cellular basal [ 3 H]palmitate uptake and a 40 -45% decrease in insulinstimulated fatty acid influx (Fig. 4C) .
Fatty Acid Reesterification Regulates AMPK in 3T3-L1 Adipocytes-A variety of studies have demonstrated that the AMPK serves as a sensor of cellular nutrient energy status. Changes in the cellular AMP/ATP ratio lead to the AMPKdependent phosphorylation of cellular targets regulated by energy flux (26, 27) . Recent work by Ruderman and co-workers (28) have shown that during lipolytic stimulation, [AMP]/[ATP] increases and AMPK is activated. Since ACSL1 is an acyl-CoA synthetase that generates AMP as a product and ACSL1 plays a major role in fatty acid reesterification, we evaluated the regulation of AMPK in response to lipolytic stimulation. As shown in Fig. 5 , consistent with the work of Gauthier et al. (28) , AMPK is activated during forskolin-stimulated lipolysis in 3T3-L1 adipocytes. Silencing of ACSL1 protein levels led to an approximate 50% decrease in phosphorylation/activation of AMPK during both basal and forskolin-stimulated lipolysis (Fig. 5) . Forskolin stimulation of lipolysis caused a significant decrease (ϳ50%) in the phosphorylation levels of ACC, a downstream target of AMPK, in ACSL1-3 kd adipocytes as compared with Scr. Although a decrease in phospho-ACC levels in ACSL1-3 kd adipocytes was observed basally as compared with Scr, the results were not statistically significant. These results suggest that the enzymatic activity of ACSL1 facilitating fatty acid reesterification affects the cellular [AMP]/[ATP] ratio sufficiently to regulate AMPK.
ACSL1-silenced adipocytes exhibited decreased phosphorylation/activation of AMPK and phosphorylation/inactivation of ACC, a rate-limiting enzyme in de novo lipogenesis, indicating that ACSL1-3 kd adipocytes may have increased rates of de novo lipogenesis. Therefore, we evaluated de novo lipogenesis in ACSL1-3 kd and control cell lines by assaying the incorporation of [
14 C]acetate into lipid pools under basal conditions and with insulin and forskolin stimulation. As shown in Fig. 6 , de novo lipogenesis under insulin and forskolin-stimulatory conditions was indistinguishable between ACSL1-3 and Scr adipocytes, but there was a slight decrease under basal conditions. ACSL1-silenced adipocytes display a significantly reduced activation of AMPK that correlates in some systems with reduced fatty acid oxidation. However, increased fatty acid availability during basal and forskolin-stimulated lipolysis may lead to increased oxidation of fatty acids. To determine if ACSL1 silencing affected fatty acid oxidation, we evaluated incomplete and complete oxidation of fatty acids by measuring incorporation of radioactivity from [1- 14 C]palmitic acid into acid-soluble metabolites and CO 2 , respectively. Although the amount of fatty acid oxidation was quite low (ϳ1-2% of internalized levels), our results indicated that there was no significant difference in lipid oxidation between the cell types (Fig. 7) .
Insulin Signaling in ACSL1-silenced 3T3-L1 AdipocytesSeveral studies have indicated a positive effect of AMPK activation on glucose homeostasis and insulin sensitivity (29) . Also, high levels of free fatty acids in the plasma have been shown to induce insulin resistance (30) . Since silencing of ACSL1 in adipocytes led to a significant decrease in AMPK activation and an increased availability of free fatty acids during basal and stimulated lipolysis, we evaluated the effect of an ACSL1 knockdown on insulin sensitivity by analyzing basal and insulin-stimulated 2-deoxyglucose uptake. Interestingly, there was a ϳ25% decrease in insulin-stimulated glucose uptake in ACSL1 kd adipocytes compared with the control. There was no significant difference in basal glucose uptake in either cell type (Fig. 8A) .
In an attempt to delineate the molecular mechanisms underlying the attenuated insulin-stimulated glucose transport in ACSL1-silenced cells, we treated Scr and ACSL1-3 kd adipocytes with insulin for 15 min and assessed components of the insulin signaling pathway. As shown in Fig. 8B , with insulin stimulation, the levels of IRS-1, IRS-1 tyrosine phosphorylation, and Akt Ser 472/473 phosphorylation were decreased, whereas IRS-1 Ser 307 phosphorylation was slightly increased in ACSL1 kd adipocytes when compared with the control cells. No changes were observed in the levels of Akt protein or Akt Thr 308 phosphorylation. There was also an increase in phosphorylation of PKC at Thr 538 and JNK at Thr 183 /Tyr 185 in ACSL1 kd adipocytes when compared with the control cells. However, no changes in the levels of total PKC and JNK were observed between both cell types. Quantitative analysis of immunoblots (Fig. 8C ) indicated a significant 9-fold increase and a 3-fold increase in phospho-PKC/ PKC and phospho-JNK/JNK ratios, respectively, in ACSL1-3 kd when compared with Scr adipocytes under basal conditions. Insulin stimulation caused a considerable 50 and 60% decrease in phospho-AKT/AKT and phospho-IRS-1(Tyr)/IRS-1 ratios, respectively, in ACSL1-3 kd when compared with Scr adipocytes.
DISCUSSION
In an effort to analyze protein-meditated fatty acid influx in adipocytes, we have taken a systematic approach by silencing the expression of putative fatty acid transporters and evaluating their contribution to overall fatty acid influx, efflux, and reesterification (6) . Overexpression studies have often led to different conclusions concerning effectors of fatty acid influx due to changes in protein levels and cellular location (6, 31, 32) , and as such, we have focused our efforts on loss of function models. Our initial studies confirmed a major role of FATP1 in facilitating insulin-stimulated fatty acid uptake, whereas silencing of FATP4 had little influence on basal or insulin-stimulated fatty acid uptake (6) . CD36 has been shown in knock-out mouse models to have a major role in adipocyte fatty acid uptake (5), and our studies reported herein confirm that finding for both basal and insulin-stimulated fatty acid influx (Fig. 4) .
In this report, we have focused our attention on the role of ACSL1 as a putative lipid transporter facilitating LCFA influx into adipocytes. ACSL1 was identified using a functional cloning strategy as a fatty acid transport protein, and subsequent studies have shown that some, but not all, ACSL1 protein localized to the plasma membrane and colocalized with FATP1 (14) . Moreover, overexpression of ACSL1 in fibroblasts led to an increase in fatty acid uptake (9) . Since ACSL1 is a robust acyl-CoA synthetase, and fatty acid influx is facilitated by acyl-CoA formation, the role of ACSL1 in vectoral acylation has been broadly assumed. Surprisingly, our experiments with ACSL1-silenced 3T3-L1 adipocytes suggest a role for the protein not in fatty acid influx but in reacylation of lipid released from the TAG droplet during basal and hormone-stimulated lipolysis (Fig. 3) . Contrary to prior assumptions, our results do not support a role for ACSL1 in either basal or insulin-stimulated fatty acid influx (Fig. 4) . In support of our results, proteomic methods identified ACSL1 as a lipid droplet-associated protein in both basal and lipolytically stimulated 3T3-L1 adipocytes (13) . One cautionary note with regard to these conclusions is that they are derived within the context of a cell culture model of adipocyte function. Additional experiments must be performed utilizing an animal model to corroborate the findings.
Our work also builds upon the recent findings by Gauthier et al. (28) , who reported that lipolysis leads to an increase in the [AMP]/[ATP] ratio, subsequently activating AMPK, and that the addition of triacsin C, a pharmacologic inhibitor of ACSL1, attenuated this effect. ACSL1, by virtue of its location on the lipid droplet and role in fatty acid reesterification and AMP formation during lipolysis, may be a prime regulator of the AMP-activated protein kinase. Work presented herein demonstrates that ACSL1-3 kd adipocytes have a lower levels of phosphorylated AMPK when compared with Scr, under both basal and forskolin-stimulated conditions. The fatty acyl-CoA synthetase activity of ACSL1 is known to utilize ATP and generate AMP during each reaction cycle. Our results imply that the fatty acid reesterification activity of ACSL1 is sufficient to affect the phosphorylation state of AMPK. AMPK in its activated state regulates downstream pathways, such as de novo lipogenesis via phosphorylation of ACC, thereby inhibiting concomitant lipid synthesis and hydrolysis (33) . Consistent with this, ACSL1-3 kd adipocytes have decreased phosphorylation levels of ACC when compared with Scr adipocytes under forskolin-stimulated conditions. Based on these results, we anticipated an increase in the amount of acetate incorporated into lipid pools. However, there was no change with insulin or forskolin-stimulated lipogenesis and a slight decrease in basal lipogenesis in ACSL1-3 kd adipocytes compared with the control cells. The reason for the small decrease in basal lipogenesis is unknown but could be complicated by several factors, including compensatory changes in gene expression or inhibition of fatty acid synthesis by fatty acids and/or acyl CoAs (34, 35) .
During lipolysis, increased availability of fatty acids in ACSL1 kd adipocytes could lead to increased ␤-oxidation. Although white adipose tissue and 3T3-L1 adipocytes do very little lipid oxidation compared with brown fat and skeletal and cardiac muscle, analysis of fatty acid oxidation using [1- 14 C]palmitate infusion revealed no difference between ACSL1-3 kd and Scr adipocytes, suggesting that this pathway is not affected by ACSL1 or is a minor contributor to overall lipid flux. In contrast, ACSL1 is abundantly expressed in tissues, such as liver and brown fat, that metabolize substantial amounts of triglycerides as fuel, and as such, a deficiency in ACSL1 function could have a more profound affect in those cells, resulting in hepatosteatosis and potentially increased very low density lipoprotein production by the liver or decreased thermogenic capacity in brown adipose tissue.
ACSL1-silenced adipocytes have reduced insulin-stimulated glucose uptake when compared with control adipocytes. ACSL1-3 kd adipocytes also demonstrated a significant increase (ϳ7-fold) in fatty acid release under basal conditions when compared with controls. Fatty acids have been shown to activate protein kinase C isoforms, such as PKC, which leads to the activation of downstream serine kinases, such as JNK and IB kinase. Activation of JNK via phosphorylation leads to increased serine (Ser 307 ) phosphorylation of the IRS-1, inhibiting its interaction with the insulin receptor and promoting IRS-1 degradation (36) . Reduction in IRS-1 protein levels attenuates phosphatidylinositol-3 kinase activation, diminishing Akt phosphorylation and thereby reducing glucose transport, producing an insulin-resistant state. In the ACSL1-silenced adipocytes, there are increased levels of PKC and JNK phosphorylation, a small increase in IRS-1 Ser 307 phosphorylation, decreased abundance of IRS-1 protein, and decreased IRS-1 tyrosine phosphorylation and Akt serine phosphorylation, all of which are consistent with insulin-resistant glucose uptake.
Fatty acid uptake into 3T3-L1 adipocytes does not affect the phosphorylation status of PKC, because the internalized lipid is readily converted to their acyl-CoA derivatives and metabolized into triacylglycerol, thereby having little effect on intracellular fatty acid levels. However, lipolysis increases intracellular fatty acid availability, particularly in ACSL1-silenced adipocytes that may affect the phosphorylation state of PKC. As such, our studies suggest that fatty acid efflux rather than influx is likely to affect free fatty acid levels and activation of downstream targets, thereby modifying the insulin responsiveness of the cells.
In sum, our findings present a new model for fatty acid flux in adipocytes, with CD36 and FATP1 playing major roles in fatty acid influx and ACSL1 facilitating reesterification of fatty acids derived from triglyceride hydrolysis. Intracellular fatty acid levels, therefore, are regulated by a balance between production at the lipid droplet, reesterification, and efflux. Such fatty acids may be regulators of signaling kinases (AMPK, PKC, and JNK) that in turn affect cellular homeostasis (Fig. 9) . The spatial and organizational integration of such processes is regulated by a complex set of determinants involving regulation of gene expression, protein localization, lipid availability, and enzyme control. Current work focuses on how such integration may be coordinated under conditions such as obesity and insulin resistance.
